PMID- 23085780
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121023
LR  - 20231105
IS  - 2044-5385 (Electronic)
IS  - 2044-5385 (Linking)
VI  - 2
IP  - 10
DP  - 2012 Oct 19
TI  - Managing chronic myeloid leukemia patients intolerant to tyrosine kinase 
      inhibitor therapy.
PG  - e95
LID - 10.1038/bcj.2012.30 [doi]
AB  - The outcomes for patients with chronic myeloid leukemia have improved 
      dramatically with the development and availability of BCR-ABL1 tyrosine kinase 
      inhibitors (TKIs) over the past decade. TKI therapy has a superior safety profile 
      compared with the previous standard of care, interferon-alpha, and most adverse 
      events (AEs) observed with front-line and second-line TKI treatment are managed 
      with supportive care. However, some patients are intolerant to TKI therapy and 
      experience AEs that cannot be managed through dose reduction or symptomatic 
      treatment. Careful management of AEs helps patients to remain adherent with 
      treatment and increases their chances for successful outcomes. Proactive 
      vigilance for potential AEs and treatment strategies that reduce symptom burden 
      will help to minimize patient intolerance. This review discusses the most common 
      AEs associated with intolerance to TKI therapy and treatment strategies to help 
      manage patients at risk for or experiencing these events.
FAU - Deangelo, D J
AU  - Deangelo DJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20121019
PL  - United States
TA  - Blood Cancer J
JT  - Blood cancer journal
JID - 101568469
PMC - PMC3483619
EDAT- 2012/10/23 06:00
MHDA- 2012/10/23 06:01
PMCR- 2012/10/01
CRDT- 2012/10/23 06:00
PHST- 2012/10/23 06:00 [entrez]
PHST- 2012/10/23 06:00 [pubmed]
PHST- 2012/10/23 06:01 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - bcj201230 [pii]
AID - 10.1038/bcj.2012.30 [doi]
PST - epublish
SO  - Blood Cancer J. 2012 Oct 19;2(10):e95. doi: 10.1038/bcj.2012.30.